SLC22A6 and Patent ductus arteriosus: Several studies have demonstrated the sensitivity of PDA plasma and urine levels to probenecid inhibition (strong OAT1/3 clinical inhibitor) [17, 19, 20], whereas no interaction was observed with inhibitors of other hepatic and renal transporters [20].